Abstract
How do normal tissues limit the development of cancer? This review discusses the evidence that normal cells effectively restrict malignant behavior, and that such tissue forces must be subjugated to establish a tumor. The action of ionizing radiation will be specifically discussed regarding the disruption of the microenvironment that promotes the transition from preneoplastic to neoplastic growth. Unlike the highly unpredictable nature of genetic mutations, the response of normal cells to radiation damage follows an epigenetic program similar to wound healing and other damage responses. Our hypothesis is that the persistent disruption of the microenvironment in irradiated tissue compromises its ability to suppress carcinogenesis.
Similar content being viewed by others
REFERENCES
M. J. Bissell and M. H. Barcellos-Hoff (1987). The influence of extracellular matrix on gene expression: Is structure the message? J. Cell Sci. 8:327–343.
G. B. Pierce, R. Shikes, and L. M. Fink (1978). Cancer: A Problem of Developmental Biology. Prentice-Hall, Inc., Englewood Cliffs, New Jersey.
C. Grobstein (1967). Mechanism of organogenetic tissue interaction. Natl. Cancer Inst. Monogr. 26:279–299.
K. Kratochwil (1969). Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev. Biol. 20:46–71.
E. Fuchs and J. A. Segre (2000). Stem cells:Anew lease on life. Cell 100:143–155.
G. Evan and T. Littlewood (1998). A matter of life and cell death. Science 281:1317–1322.
E. Farber (1984). The multistep nature of cancer development. Cancer Res. 44:4217–4223.
R. A. Weinberg (1989). Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49:3713–3721.
S. H. Kim, K. A. Roth, A. R. Moser, and J. I. Gordon (1993). Transgenic mouse models that explore the multistep hypothesis of intestinal neoplasia. J. Cell Biol. 123:877–893.
A. van den Hoof (1988). Stromal involvement in malignant growth. Adv. Cancer Res. 50:159–196.
M. Skobe and N. E. Fusenig (1998). Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc. Natl. Acad. Sci. U.S.A. 95:1050–1055.
K. W. Kinzler and B. Vogelstein (1997). Cancer-susceptibility genes. Gatekeepers and caretakers [news; comment]. Nature 386:761, 763.
K.W. Kinzler and B. Vogelstein (1998). Landscaping the cancer terrain [comment]. Science 280:1036–1037.
D. Hanahan and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100:57–50.
M. Terzaghi and P. Nettesheim (1979). Dynamics of neoplastic development in carcinogen-exposed tracheal mucosa. Cancer Res. 39:3004–3010.
R. L. Ullrich (1986). The rate of progression of radiationtransformed mammary epithelial cells is enhanced after lowdose-rate neutron irradiation. Rad. Res. 105:68–75.
K. Kamiya, J. Yasukawa-Barnes, J. M. Mitchen, M. N. Gould, and K. H. Clifton (1995). Evidence that carcinogenesis involves an imbalance between epigenetic high-frequency initiation and suppression of promotion. Proc. Natl. Acad. Sci.U.S.A. 92:1332–1336.
G. Bauer (1996). Elimination of transformed cells by normal cells: A novel concept for the control of carcinogenesis. Histol. Histopathol. 11:237–255.
I. Engelmann and G. Bauer (2000). How can tumor cells escape intercellular induction of apoptosis? Anticancer Res. 20:2297–2306.
I. Engelmann, H. Eichholtz-Wirth, and G. Bauer (2000). Ex vivo tumor cell lines are resistant to intercellular induction of apoptosis and independent of exogenous survival factors. Anticancer Res. 20:2361–2370.
M. Terzaghi-Howe (1986). Inhibition of carcinogen-altered rat tracheal epithelial cell proliferation by normal epithelial cells in vivo. Carcinogenesis 8:145–150.
G.-W. Chang and M. Terzaghi-Howe (1998). Multiple changes in gene expression are associated with normal cell-induced modulation of the neoplastic phenotype. Cancer Res. 58:4445–4452.
M. M. Zutter, S. A. Santoro, W. D. Staatz, and Y. L. Tsung (1995). Re-expression of the ?2? 1 integrin abrogates malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 92:7411–7415.
V. M. Weaver, O. W. Petersen, F. Wang, C. A. Larabell, P. Briand, C. Damsky, and M. J. Bissell (1997). Reversion of the malignant phenotype of human breast cells in threedimensional culture and in vivo by integrin blocking antibodies. J.Cell Biol. 137:231–245.
R. Bhatia, J. B. McCarthy, and C. M. Verfaillie (1996). Interferon-? restores normal ?1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87:3883–3891.
J. B. Little (2000). Radiation carcinogenesis. Carcinogenesis 21:397–404.
C. L. Limoli, M. I. Kaplan, J. Corcoran, M. Meyers, D. A. Boothman, and W. F. Morgan (1997). Chromosomal instability and its relationship to other end points of genomic instability. Cancer Res. 57:5557–5563.
E. I. Azzam, S. M. de Toledo, T. Gooding, and J.B. Little (1998). Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of ? particles. Rad. Res. 150:497–504.
B. E. Lehnert and E. H. Goodwin(1997). Extracellular factor(s) following exposure to ? particles can cause sister chromatid exchanges in normal human cells. Cancer Res. 57:2164–2171.
M. Chow and H. Rubin (1999). The cellular ecology of progressive neoplastic transformation: A clonal analysis. Proc. Natl. Acad. Sci. U.S.A. 96:2093–2098.
J. E. Trosko, C. C. Chang, and B. V. Madhukar (1990). Modulation of intercellular communication during radiation and chemical carcinogenesis. 123:241–251.
I. Tomlinson and W. Bodmer (1999). Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nature Med. 5:11–12.
I. P. Tomlinson, M. R. Novelli, and W. F. Bodmer (1996). The mutation rate and cancer. Proc. Natl. Acad. Sci. U.S.A. 93:14800–14803.
J. J. Decosse, C. L. Gossens, J. F. Kuzma, and D. Unsworth (1973). Breast cancer: Induction of differentiation by embryonic tissue. Science 181:1057–1058.
M. Cooper and H. Pinkus (1977). Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. 37:2544–2552.
S. L. Schor, A. M. Schor, A. Howell, and J. Haggie (1988). The possible role of abnormal fibroblasts in the phathogenesis of breast cancer. In M. A. Rich, J. C. Hager, and D. M. Lopez, (eds.), Breast Cancer: Scientific and Chemical Progress, Kluwer Academic Publishers, Boston, pp. 142–157.
S. L. Schor, A. M. Schor, A. Howell, and D. Crowther (1987). Hypothesis: Persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. Expl. Cell Biol. 55:11–17.
S. L. Schor, A. M. Schor, P. Durning, and G. Rushton (1985). Skin fibroblasts obtained from cancer patients display foetallike migratory behavior on collagen gels. J. Cell Sci. 73:235–244.
A. M. Schor, G. Rushton, J. E. Ferguson, A. Howell, J. Redford, and S. L. Schor (1994). Phenotypic heteogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int. J. Cancer 59:25–32.
J. A. Haggie, S. L. Schor, A. Howell, J. M. Birch, and R. A. S. Sellwood (1987). Fibroblasts from relatives of hereditary breast cancer patients display fetal-like behavior in vitro. Lancet 1:1455–1457.
D. Medina, F. Shepherd, and T. Gropp (1978). Enhancement of the tumorigenicity of preneoplastic mammary nodule lines by enzymatic dissociation. JNCI 60:1121–1126.
T. Sakakura, Y. Sakagami, and Y. Nishizuka (1979). Persistence of responsiveness of adult mouse mammary gland to induction by embryonic mesenchyme. Dev. Biol. 72:201–210.
T. Sakakura, Y. Sakagami, and Y. Nishizuka (1981). Accelerated mammary cancer development by fetal salivary mesenchyme isografted to adult mouse mammary epithelium. J. Natl. Cancer Inst. 66:953–959.
M. Y. Gordon, C. R. Dowding, G. P. Riley, J. M. Goldman, and M. F. Greaves (1987). Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342–344.
M. H. Sieweke and M. J. Bissell (1994). The tumor promoting effect of wounding: A possible role for TGF? induced fibrotic stroma. Crit. Rev. Oncogenesis 5:297–311.
B. Fisher and E. R. Fisher (1968). Role of host and tumor calcium in metastases. Cancer Res. 28:1753–1758.
D. S. Dolberg, R. Holingworth, M. Hertle, and M. J. Bissell (1985). Wounding and its role in RSV-mediated tumor formation. Science 230:676–678.
A. C. Schuh, S. F. Keating, F. S. Moneclaro, P. K. Vogt, and M. L. Breitman (1990). Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature 346:756–760.
A. Lochter, S. Galosy, J. Muschler, N. Freedman, Z. Werb, and M. J. Bissell (1997). Matrix metalloproteinase stomelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and premalignant phentoype in mammary epithelial cells. J. Cell Biol. 139:1861–1872.
N. Thomasset, A. Lochter, C. J. Sympson, L. R. Lund, D. R. Williams, O. Behrendtsen, Z. Werb, and M. J. Bissell (1998). Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. J. Amer. Sci. 153:457–467.
J. E. Trosko (1998). Hierarchcal and cybernetic nature of biologic systems and their relevance to homeostatic adaptation to low-level exposures to oxidative stress-inducing agents. Environ. Health Perspect. 106:331–339.
M. H. Barcellos-Hoff (1993). Radiation-induced transforming growth factor ? and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res. 53:3880–3886.
M. H. Barcellos-Hoff, R. Derynck, M. L.-S. Tsang, and J. A. Weatherbee (1994). Transforming growth factor-? activation in irradiated murine mammary gland. J. Clin. Invest. 93:892–899.
E. J. Ehrhart, A. Carroll, P. Segarini, M. L.-S. Tsang, and M. H. Barcellos-Hoff (1997). Latent transforming growth factor-? activation in situ: Quantitative and functional evidence following low dose irradiation. FASEB J. 11:991–1002.
M. H. Barcellos-Hoff (1998). How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Rad. Res. 150:S109–S120.
M. H. Barcellos-Hoff (1998). The potential influence of radiation-induced microenvironments in neoplastic progression. J. Mam. Gland Biol. Neoplasia 3:165–175.
M. H. Barcellos-Hoff and S. A. Ravani (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:1254–1260.
J. Greenberger, M. Epperly, A. Zeevi, K. Brunson, K. Goltry, K. Pogue-Geile, J. Bray, and L. Berry (1996). Stromal cell involvement in leukemogenesis and carcinogenesis. InVivo 10:1–17.
J. T. Leith and S. Michelson (1990). Tumor radiocurability: Relationship to intrinsic tumor eterogeneity and to the tumor bed effect. Invasion Metastasis 10:329–351.
L. T. Bemis and P. Schedin (2000). Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 60:3414–3418.
G. M. Hodges, R.M. Hicks, and G.D. Spacey (1977). Epithelialstromal interactions in normal and chemical carcinogen-treated adult bladder. Cancer Res. 37:3720–3730.
R. S. Cha, W. G. Thilly, and H. Zarbl (1994). N-nitroso-Nmethylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1 gene mutations. PNAS 91:3749–3753.
A. Haimovitz-Friedman, I. Vlodavsky, A. Chaudhuri, L. Witte, and Z. Fuks (1991). Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res. 51:2552–2558.
D. M. Gadbois and B. E. Lehnert (1997). Control of radiationinduced G1 arrest by cell-substratum interactions. Cancer Res. 57:1151–1156.
S. Kondo (1988). Altruistic cell suicide in relation to radiation hormesis. Int. J. Radiat. Biol. Phys. Chem. Med. 53:95–102.
C. Nathan and M. Sporn (1991). Cytokines in context. J.Cell Biol. 113:981–986.
A.B. Roberts, N.L. Thompson, U. Heine, C. Flanders, and M.B. Sporn (1988). Transforming growth factor-?: Possible roles in carcinogenesis. Brit. J. Cancer 57:594–600.
J. Massague, S.W. Blain, and R. S. Lo (2000). TGF-? signaling in growth control, cancer, and heritable disorders. Cell 103:295–309.
M. W. J. Ferguson (1994). Skin wound healing: Transforming growth factor ? antagonists decrease scarring and improve quality. J. Interferon Res. 14:303–304.
G. S. Ashcroft, X. Yang, A. B. Glick, M. Weinstein, J. L. Letterio, D. E. Mizel, M. Anzano, T. Greenwell-Wild, S. M. Wahl, C. Deng, and A. B. Roberts (1999). Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol. 1:260–266.
T. Ohmori, J. L. Yang, J. O. Price, and C. L. Arteaga (1998). Blockade of tumor cell transforming growth factor-?s enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Exp. Cell Res. 245:350–359.
B. A. Teicher, Y. Maehara, Y. Kakeji, G. Ara, S. R. Keyes, J. Wong, and R. Herbst (1997). Reversal of in vivo drug resistance by the transforming growth factor-? inhibitor decorin. Int. J. Cancer 71:49–58.
T. Häufel, S. Dormann, J. Hanusch, A. Schwieger, and G. Bauer (1999). Three distinct roles for TGF-? during intercellular induction of apoptosis: A review. Anticancer Res. 19: 105–111.
M. H. Sieweke, N. L. Thompson, M. B. Sporn, and M. J. Bissell (1990). Mediation of wound-related Rous sarcoma virus tumorigenesis and TGF-?. Science 248:1656–1660.
G. Furstenberger, M. Rogers, R. Schnapki, G. Bauer, P. Hofler, and F. Marks (1989). Stimulatory role of transforming growth factors in multistage skin carcinogenesis: Possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. Int. J. Cancer 43:915–921.
T. M. Fynan and M. Reiss (1993). Resistance to inhibition of cell growth by transforming growth factor-? and its role in oncogenesis. Crit. Rev. Oncogen. 4:493–540.
D. F. Pierce, A. E. Gorska, A. Chythil, K. S. Meise, D. L. Page, R. J. Coffey, Jr., and H. L. Moses (1995). Mammary tumor suppression by transforming growth factor ?1 transgene expression. Proc. Natl. Acad. Sci. U.S.A. 92:4254–4258.
W. Cui, D. J. Fowlis, S. Bryson, E. Duffie, H. Ireland, A. Balmain, and R. J. Akhurst (1996). TGF?1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86:531–542.
G. Portella, S. A. Cumming, J. Liddell, W. Cui, H. Ireland, R. J. Akhurst, and A. Balmain (1998). Transforming growth factor ? is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ. 9:393–404.
C. Amendt, P. Schirmacher, H. Weber, and M. Blessing (1998). Expression of a dominant negative type II TGF-? receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17:25–34.
E. D. Hay(1995). An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1:8–20.
B. Tang, E. P. Bottinger, S. B. Jakowlew, K. M. Bangall, J. Mariano, M. R. Anver, J. J. Letterio, and L. M. Wakefield (1998). Transforming growth factor-?1 is a new form of tumor supressor with true haploid insufficiency. Nature Medicine 4:802–807.
M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, M. Lagman, T. Shimbo, and M. Suthanthiran (1999). Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534.
A. B. Glick, W.C. Weinberg, I. H. Wu, W. Quan, and S. H. Yuspa (1996). Transforming growth factor ?1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res. 56:3645–3650.
A. Glick, N. Popescu, V. Alexander, H. Ueno, E. Bottinger, and S. H. Yuspa (1999). Defects in transforming growth factor-? signaling cooperate with a Ras oncogene to cause rapid aneuploidy and malignant transformation of mouse keratinocytes. Proc. Nat. Acad. of Sci. U.S.A. 96:14949–14954.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barcellos-Hoff, M.H. It Takes a Tissue to Make a Tumor: Epigenetics, Cancer and the Microenvironment. J Mammary Gland Biol Neoplasia 6, 213–221 (2001). https://doi.org/10.1023/A:1011317009329
Issue Date:
DOI: https://doi.org/10.1023/A:1011317009329